BiotechTube
Cell BioEngines

Cell BioEngines

Cambridge, United States· Est.
cellbioengines.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37.2M

Overview

Cell BioEngines is an emerging player in the allogeneic cell therapy space, leveraging a proprietary 'super-donor' stem cell platform to create transgene-free, scalable therapies. Its strategy combines HLA-guided design with a population-informed biobank to achieve broad patient coverage across multiple diseases. The company operates with a therapeutic area-agnostic, portfolio-focused business model aimed at reducing development time, translational costs, and overall risk.

OncologyRegenerative Medicine

Technology Platform

STEM-Space™ Platform: A transgene-free, chemical reprogramming platform to create 'super-donor' stem cells. It combines HLA-guided design and a population-informed biobank for scalable manufacturing of allogeneic, off-the-shelf cell therapies.

Funding History

2
Total raised:$37.2M
Series A$32M
Seed$5.2M

Opportunities

The global shift towards off-the-shelf, scalable cell therapies presents a multi-billion dollar market in oncology and regenerative medicine.
The company's focus on low-cost, transgene-free manufacturing and broad patient coverage via HLA-matching could address key cost and accessibility barriers, attracting partnership and payer interest.

Risk Factors

High technical risk in proving the efficacy and safety of its novel transgene-free platform against established gene-editing approaches.
Significant clinical and regulatory uncertainty as a first-in-class technology, coupled with intense competition in the allogeneic cell therapy space from well-capitalized players.

Competitive Landscape

Cell BioEngines operates in the highly competitive allogeneic cell therapy arena, competing directly with companies using CRISPR and other gene-editing tools to create off-the-shelf CAR-T and NK cell therapies (e.g., Allogene, CRISPR Therapeutics, Fate Therapeutics). Its key differentiator is the avoidance of permanent genetic modification, which it must prove is not a disadvantage in terms of potency or durability.

More companies in Cell & Gene Therapy →More companies in United States →